BG99261A - Steroid glycosides for the treatment of hyperchlesterolemia - Google Patents

Steroid glycosides for the treatment of hyperchlesterolemia

Info

Publication number
BG99261A
BG99261A BG99261A BG9926194A BG99261A BG 99261 A BG99261 A BG 99261A BG 99261 A BG99261 A BG 99261A BG 9926194 A BG9926194 A BG 9926194A BG 99261 A BG99261 A BG 99261A
Authority
BG
Bulgaria
Prior art keywords
treatment
hyperchlesterolemia
steroid glycosides
steroid
glycosides
Prior art date
Application number
BG99261A
Other languages
Bulgarian (bg)
English (en)
Inventor
Michael Deninno
Peter Mccarthy
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of BG99261A publication Critical patent/BG99261A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BG99261A 1992-06-26 1994-12-13 Steroid glycosides for the treatment of hyperchlesterolemia BG99261A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90491492A 1992-06-26 1992-06-26
PCT/US1993/004092 WO1994000480A1 (fr) 1992-06-26 1993-05-06 Glycosides steroidiens utiles dans le traitement de l'hypercholesterolemie

Publications (1)

Publication Number Publication Date
BG99261A true BG99261A (en) 1995-06-30

Family

ID=25419965

Family Applications (1)

Application Number Title Priority Date Filing Date
BG99261A BG99261A (en) 1992-06-26 1994-12-13 Steroid glycosides for the treatment of hyperchlesterolemia

Country Status (19)

Country Link
US (2) US5629295A (fr)
EP (4) EP0796862A2 (fr)
JP (2) JPH07504921A (fr)
KR (1) KR950702203A (fr)
CN (1) CN1085561A (fr)
AP (1) AP489A (fr)
AU (1) AU4226593A (fr)
BG (1) BG99261A (fr)
BR (1) BR9306619A (fr)
CA (1) CA2139104A1 (fr)
CZ (1) CZ331094A3 (fr)
HR (1) HRP930994A2 (fr)
IL (1) IL106055A0 (fr)
MX (1) MX9303826A (fr)
OA (1) OA10121A (fr)
RU (1) RU94046294A (fr)
SK (1) SK158394A3 (fr)
WO (1) WO1994000480A1 (fr)
YU (1) YU44793A (fr)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5563259A (en) * 1992-06-26 1996-10-08 Pfizer Inc. Process for making β-O-cellobiosyl steroid derivatives and trimethyl silyl steroid intermediates used therein
WO1994025479A1 (fr) * 1993-04-28 1994-11-10 Pfizer Inc. Monohydrate cristallin glycosidique de spirostanyle
US5502038A (en) * 1993-06-21 1996-03-26 Medical Research Foundation Of Oregon Cholesterol sequestrant glycosides that inhibit intestinal cholesterol absorption
ES2074006B1 (es) * 1993-07-05 1996-03-16 Pfizer Glicosidos esteroidales para tratar hipercolesterolemia.
FI96243C (fi) * 1993-10-26 1996-05-27 Ilmari Paakkinen Menetelmä ja laite rakeisten maamassojen ominaisuuksien mittaamiseksi
CA2180149A1 (fr) * 1993-12-28 1995-07-06 Michael Paul Deninno Glycosides steroidiens
CA2180148A1 (fr) * 1993-12-28 1995-07-06 Michael Paul Deninno Agents hypocholesterolemiques
FR2722690B1 (fr) * 1994-07-21 1996-10-25 Univ Montpellier Ii Compositions de saponines et/ou de leurs formes aglycones et leurs applications comme medicaments
PL318937A1 (en) * 1994-08-30 1997-07-21 Pfizer Spirostanyloglycoside crystals
US5807834A (en) * 1994-09-20 1998-09-15 Pfizer Inc. Combination of a cholesterol absorption inhibitor and a cholesterol synthesis inhibitor
WO1996038466A1 (fr) * 1995-05-29 1996-12-05 Pfizer Inc. Glycosides steroidiques
US5698527A (en) * 1995-08-08 1997-12-16 Merck & Co., Inc. Steroidal glycosides as antihyperlipidemic agents
US5756470A (en) * 1996-10-29 1998-05-26 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
ATE337788T1 (de) * 1998-03-26 2006-09-15 Phytopharm Plc Steroidale saponine zur behandlung der alzheimerischen krankheit
GB9923076D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
JP3370610B2 (ja) * 1998-08-21 2003-01-27 武田薬品工業株式会社 害虫防除剤
US20030060425A1 (en) * 1998-11-24 2003-03-27 Ahlem Clarence N. Immune modulation method using steroid compounds
GB9923078D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
US6343258B1 (en) 1999-08-13 2002-01-29 ALEXIS Brian Method for testing for readiness for harvesting of tribulus terrestris l. having high steroidal saponin content
GB9923077D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
WO2001032679A2 (fr) * 1999-11-01 2001-05-10 Forbes Medi-Tech Inc. Nouveaux glycosides contenant des mono-, di-, tri- ou oligosaccharides pentose et des phytosterols et/ou des phytostanols
GB0000228D0 (en) * 2000-01-06 2000-03-01 Phytopharm Plc Fluoro substituted sapogenins and their use
US6207638B1 (en) 2000-02-23 2001-03-27 Pacifichealth Laboratories, Inc. Nutritional intervention composition for enhancing and extending satiety
US6429190B1 (en) 2000-12-15 2002-08-06 Pacifichealth Laboratories, Inc. Method for extending the satiety of food by adding a nutritional composition designed to stimulate cholecystokinin(CCK)
AU2002232575A1 (en) 2000-12-15 2002-06-24 Pacifichealth Laboratories, Inc. Nutritional composition for improving the efficacy of a lipase inhibitor
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
KR20070120617A (ko) 2001-01-26 2007-12-24 쉐링 코포레이션 치환된 아제티딘온 화합물을 포함하는 약제학적 조성물
IL156445A0 (en) 2001-01-26 2004-01-04 Schering Corp Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
GB0107822D0 (en) * 2001-03-28 2001-05-23 Phytopharm Plc Sapogenin derivatives their synthesis and use methods based upon their use
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
EP1429756B1 (fr) 2001-09-21 2006-11-22 Schering Corporation Methodes et combinaisons therapeutiques utiles pour le traitement du xanthome effectue avec des inhibiteurs d'absorption du sterol
US6703530B2 (en) * 2002-02-28 2004-03-09 General Electric Company Chemical reactor system and process
KR101130212B1 (ko) * 2002-03-27 2012-04-13 파이토팜 피엘씨 사포게닌 및 그 유도체의 치료 방법 및 사용법
US20050130948A1 (en) * 2002-03-27 2005-06-16 Daryl Rees Therapeutic methods and uses of sapogenins and their derivatives
PL210114B1 (pl) * 2002-10-28 2011-12-30 Phytopharm Plc Sposób stereospecyficznego wytwarzania 3β-hydroksy-5β-H-steroidowych sapogenin
CA2504916A1 (fr) 2002-11-06 2004-05-27 Schering Corporation Inhibiteurs d'absorption de cholesterol pour le traitement de troubles auto-immuns
DE602004018617D1 (de) 2003-03-07 2009-02-05 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
WO2004081004A1 (fr) 2003-03-07 2004-09-23 Schering Corporation Composes d'azetidinone substitues, formulations et utilisations de ceux-ci pour traiter l'hypercholesterolemie
WO2004081002A1 (fr) 2003-03-07 2004-09-23 Schering Corporation Composes d'azetidinone substitues, leurs formulations et utilisations en vue du traitement de l'hypercholesterolemie
ES2328384T3 (es) 2004-11-23 2009-11-12 Warner-Lambert Company Llc Derivados del acido 7-(2h-pirazol-3-il)-3,5-dihidroxi-heptanoico como inhibidores de hmg co-a reductasa para el tratamiento de la lipidemia.
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
ATE547394T1 (de) 2006-12-01 2012-03-15 Bristol Myers Squibb Co N-((3-benzyl)-2,2-(bis-phenyl)-propan-1- aminderivate als cetp-hemmer für die behandlung von atherosklerose und herz-kreislauf- erkrankungen
TW201006474A (en) * 2008-04-18 2010-02-16 Reata Pharmaceuticals Inc Natural products including an anti-flammatory pharmacore and methods of use
ES2449396T3 (es) 2008-07-22 2014-03-19 Trustees Of Dartmouth College Cianoenonas monocíclicas y métodos de uso de las mismas
WO2011145022A1 (fr) 2010-05-21 2011-11-24 Pfizer Inc. 2-phénylbenzoylamides
US20130345392A1 (en) 2011-03-04 2013-12-26 Pfizer Inc Edn3-like peptides and uses thereof
CU20110244A7 (es) * 2011-12-27 2013-08-29 Ct De Investigación Y Desarrollo De Medicamentos Cidem Sistemas espiroesteroidales con efectos neuroactivos y anti-inflamatorios
CN105143203A (zh) 2013-04-17 2015-12-09 辉瑞大药厂 用于治疗心血管疾病的n-哌啶-3-基苯甲酰胺衍生物
WO2016055901A1 (fr) 2014-10-08 2016-04-14 Pfizer Inc. Composés d'amide substitué
WO2020150473A2 (fr) 2019-01-18 2020-07-23 Dogma Therapeutics, Inc. Inhibiteurs de pcsk9 et leurs procédés d'utilisation

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3178418A (en) 1963-02-26 1965-04-13 Glaxo Lab Ltd Monobromination at the 11-position of hecogenin and 3-lower alkanoyl esters thereof
DE2926463A1 (de) * 1978-07-05 1980-01-24 Roecar Holdings Nv Spiroketaline und ihre verwendung
US4260603A (en) * 1979-01-02 1981-04-07 Pegel Karl H Sterol glycoside with activity as prostaglandin synthetase inhibitor
NZ193564A (en) * 1979-05-02 1985-01-31 Aruba Pty Ltd Steroid alkaloids from solanum sodomeum and pharmaceutical compositions
US4602003A (en) 1982-05-17 1986-07-22 Medical Research Foundation Of Oregon Synthetic compounds to inhibit intestinal absorption of cholesterol in the treatment of hypercholesterolemia
US4602005A (en) * 1982-05-17 1986-07-22 Medical Research Foundation Of Oregon Tigogenin cellobioside for treating hypercholesterolemia and atherosclerosis
ES8404693A1 (es) * 1982-08-12 1984-05-01 Nativelle Sa Ets Procedimiento de preparacion de nuevos amino-14 esteroides.
ES8404694A1 (es) * 1982-08-20 1984-05-01 Nativelle Sa Ets Procedimiento de preparacion de nuevos derivos de amino-14 esteroides
IT1188184B (it) 1985-08-14 1988-01-07 Texcontor Ets Sali ammonici quaternari di polisaccaridi ad attivita' ipocolesterolemizzante
US5017562A (en) * 1987-02-11 1991-05-21 Regents Of The University Of Minnesota Crystalline saponin-containing complex
FR2621316B1 (fr) * 1987-10-02 1991-06-21 Nativelle Sa Ets Nouveaux esters d'acide androstane 17-carboxylique, procede pour leur preparation, et medicament les contenant
US5010185A (en) * 1989-06-13 1991-04-23 Pfizer Inc. Processes for tigogenin beta-cellobioside
AU658441B2 (en) * 1991-07-23 1995-04-13 Schering Corporation Substituted beta-lactam compounds useful as hypocholesterolemic agents and processes for the preparation thereof
WO1993005790A1 (fr) * 1991-09-27 1993-04-01 Procter & Gamble Pharmaceuticals, Inc. Emploi de 14-aminosteroides dans la fabrication d'un medicament destine a ralentir la vitesse de progression d'alterations structurelles myocardiques caracteristique de l'insuffisance cardiaque congestive
WO1993007167A1 (fr) * 1991-10-04 1993-04-15 The Procter & Gamble Company Composes d'abaissement du taux de cholesterol et leur procede de production
CA2123684A1 (fr) * 1991-11-25 1993-06-10 Douglas J. M. Allen Methode de fabrication de peracylglycosides steroidiens
US5530107A (en) * 1992-10-15 1996-06-25 Pfizer Inc. Method for making steroidal peracyl glycosides
LT3595B (en) * 1993-01-21 1995-12-27 Schering Corp Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents

Also Published As

Publication number Publication date
RU94046294A (ru) 1996-10-10
EP0796863A2 (fr) 1997-09-24
BR9306619A (pt) 1998-12-08
US5703052A (en) 1997-12-30
CN1085561A (zh) 1994-04-20
OA10121A (en) 1996-12-18
MX9303826A (es) 1994-02-28
US5629295A (en) 1997-05-13
SK158394A3 (en) 1995-05-10
CA2139104A1 (fr) 1994-01-06
WO1994000480A1 (fr) 1994-01-06
AU4226593A (en) 1994-01-24
EP0647234A1 (fr) 1995-04-12
HRP930994A2 (en) 1996-08-31
JPH07504921A (ja) 1995-06-01
IL106055A0 (en) 1993-10-20
KR950702203A (ko) 1995-06-19
YU44793A (sh) 1996-10-09
AP9300539A0 (en) 1993-07-31
CZ331094A3 (en) 1995-09-13
EP0796862A2 (fr) 1997-09-24
AP489A (en) 1996-05-02
EP0796864A2 (fr) 1997-09-24
JPH09309897A (ja) 1997-12-02

Similar Documents

Publication Publication Date Title
DK0973735T3 (da) Polyaromatiske antivirale præparater
BG104247A (bg) Производни на резорцинола
TR199901174T2 (xx) Yeni heterosiklilmetil-ikameli pirazol t�revleri.
DE69726577D1 (en) Kristallin form i von clarithromycin
EP0677036A4 (fr) Production de tetrahydro-isohumulates inodores.
UA39158C2 (uk) Похідні n4-оксикарбоніл-5'-дезокси-5-фторцитидину та фармацевтичний препарат на їх основі
ES2106965T3 (es) Nuevas 4-aza-5alfa-androstan-3-onas 7beta-sustituidas como inhibidores de 5alfa-reductasa.
DE69612003D1 (de) Substituierte benzolaktamverbindungen als substanz-p-antagonisten
UA26213C2 (uk) Засіб для профілактики та лікуваhhя остеопорозу та фармацевтичhа композиція hа їх осhові
IL114294A0 (en) Sterol derivatives
YU44793A (sh) Spirostanil glikozidi za lecenje hiperholesterolemije
BG102250A (en) The use of marigold-extracted glycosides for the treatment of psoriasis
PT902789E (pt) Derivados de androsteno
AU7619291A (en) Use of baclofen for obtaining medicaments for the treatment of angina pectoris
FI895064A7 (fi) Syklosporiinia sisältäviä koostumuksia silmätulehdusten hoitoon
ATE203519T1 (de) Chinolinderivate als antimalariamittel
DE69405919D1 (de) Zusammensetzungen zur Behandlung von Keratinfasern
MX9101958A (es) Inhibidores de acat de urea de aminosulfonilo
NO980296D0 (no) Forbedrede terapeutiske midler
MD960168A (ro) Metodă şi compuşi pentru tratamentul infecţiilor virale
DE69613395D1 (de) Schwefelenthaltende di-ter-butylphenol-verbindungen brauchbar als entzündungshemmende mittel
ATE160573T1 (de) 1,3.5 (10) - estratriene derivate mit oraler wirkung
EP0710484A3 (fr) Mélange de alpha-D-glucopyranosyl-(1-6)-alpha-D glucopyranose comme agent antitumoral
DE69917445D1 (de) Reinigung von carboxaldehyd
ZA949564B (en) Method for treating constipation using dimeticone.